Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults

• Status: Terminated
• Trial end date: 2011-08-01

Summary

This study is designed to look at the potential for an investigational drug (PF-04995274, under development by Pfizer, Inc. as a potential treatment for Alzheimer's disease) to reverse changes in memory and learning/problem solving skills caused by co-administration of a marketed drug called scopolamine. Scopolamine is known to cause temporary changes in memory and learning/problem solving skills that are similar to those seen in people with alzheimer's disease(AD).

• Phase: Phase 1

Details

• Lead Sponsor: Pfizer
• Treatments: Butylscopolammonium Bromide; Donepezil; Scopolamine; Scopolamine Hydrobromide